Het cholinerge deficiëntiesyndroom als indicatie voor cholinesteraseremmers

Translated title of the contribution: Cholinergic deficiency syndrome as an indicator for cholinesterase inhibitors

Research output: Contribution to journalReview articleAcademicpeer-review

6 Citations (Scopus)


Cholinesterase inhibitors are licensed for the treatment of dementia in Alzheimer's disease. In clinical practice, these drugs have little effect on the cognitive symptoms of dementia. Several studies report a beneficial effect of cholinesterase inhibitors on neuropsychiatric symptoms. We hypothesise that symptoms such as the impairment of attention and concentration, anxiety, restlessness and hallucinations, delineate a specific central cholinergic deficiency syndrome. It is postulated that this syndrome crosses boundaries of nosological entities and occurs in various neurodegenerative diseases. Symptoms resulting from cholinergic deficiency might be a much better target for treatment than cognitive deficits.

Translated title of the contributionCholinergic deficiency syndrome as an indicator for cholinesterase inhibitors
Original languageDutch
Pages (from-to)2201-2203
Number of pages3
JournalNederlands Tijdschrift voor Geneeskunde
Issue number45
Publication statusPublished - 8 Nov 2003

Cite this